All articles by Taylor Mixides (Drug Target Review) – Page 4
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
-
ArticleNeoantigen-directed cancer treatment
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
-
ArticleBreakthrough drug candidates and cancer treatment innovations
In this exclusive interview with Dr Paul Moore, Chief Scientific Officer from Zymeworks, we explore the impressive responses of Zymeworks' antibody-drug conjugate ZW191 in FRα-low expressing models, indicating its efficacy in treating various oncology indications.
-
ArticlePromising human antibodies fighting SARS-CoV-2
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to ...
-
NewsPlacenta's role in genetic risk of schizophrenia
A recent study led by the Lieber Institute for Brain Development has revealed that over 100 genes associated with the risk of schizophrenia appear to contribute to the development of the illness primarily through their influence on the placenta.
-
NewsNew gene linked to Malaria parasite's chloroquine resistance
Researchers have important implications for the ongoing fight against malaria, a disease that affects approximately 247 million individuals and causes over 619,000 deaths each year, predominantly among young children.
-
NewsGut bacterial interactions limit antibiotic efficacy on C. difficile
A recent study from the University of Wisconsin-Madison suggests that interactions between gut bacteria can influence the effectiveness of antibiotics against C. difficile infections.
-
ArticleNew insight into BRCA2 gene mutations and cancer risk
A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovarian cancer.
-
ArticleChallenges and promises of personalised precision medicine
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
-
News
Brain cells found to transfer material to neurons in mice
Researchers have discovered that oligodendrocyte-lineage cells transfer cell material to neurons in a mouse brain. They have provided the first evidence of coordinated nuclear interaction between these cells and neurons.
-
NewsCombination therapy prevails against BET inhibitor resistance
St. Jude Children's Research Hospital, US, scientists created a new combination therapy method to tackle drug resistance in a type of leukaemia with KMT2A gene rearrangement.
-
NewsAccelerating the immune system could eliminate ageing cells
Boosting the body’s anti-viral immune response could restore tissue balance and eliminate ageing cells that contribute to age-related diseases.
-
NewsNew drug provides optimism for individuals suffering from heart failure
A newly developed drug displays potential in treating both heart failure and the related sleep apnea.
-
NewsArtificial sweeteners weaken mice's immune response to disease
New findings in mice using artificial sweeteners could result in new therapies to regulate the immune system in those with autoimmune diseases, potentially improving outcomes.
-
NewsMouse study at USC reveals why leukemic mutation varies
A mechanism linked to a genetic mutation could help identify patients who are at higher risk of developing leukaemia.
-
News
The immune system's power over antibiotics for infections
The natural process of removing damaged cell parts could present an alternative to antibiotics, especially where bacteria have become resistant to existing drugs.
-
NewsNeutralising COVID-19 therapeutic antibodies
The Omicron variant of the SARS CoV-2 virus has previously had a number of break-through infections. However, researchers have discovered that antibodies present in previously infected patients can neutralise variants of the COVID-19 disease.
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page